News | Peripheral Artery Disease (PAD) | November 09, 2018

iDissection Classification Study to Evaluate Dissection Rate of Flex Dynamic Scoring Catheter

New study to determine if Flex Catheter reduces dissections and the need for bailout stents in peripheral arteries

iDissection Classification Study to Evaluate Dissection Rate of Flex Dynamic Scoring Catheter

November 9, 2018 — VentureMed Group Inc. announced the initiation of a new study to determine if the Flex Dynamic Scoring Catheter reduces dissections and the need for bailout stents in peripheral arteries. The study, entitled “Arterial Dissections Following FLEX Scoring and Adjunctive Balloon Angioplasty: Intravascular Ultrasound Assessment and Correlation with Angiographic Findings,” will utilize intravascular ultrasound (IVUS) to identify the health of the vessel after treatment.

Nicolas W. Shammas, M.D., founder and director of the Midwest Cardiovascular Research Foundation in Davenport, Iowa is the principal investigator for the study. This study is the second iDissection study performed by Shammas. The first study revealed that after atherectomy, in the peripheral arteries, significant dissections are more visible by a ratio of 6:1 when using IVUS in comparison to the typical angiogram. Deducing that the presence and severity of dissection after atherectomy may have been underestimated, especially for deeper dissections which are associated with recurrent restenosis, recoil and possibly acute closure.

“After the indicative results of the initial iDissection study, I am motivated to look for vessel prep devices that further reduce the need for provisional stenting,” said Shammas. “I am optimistic about the ability of the Flex Catheter to reduce the rate of high-grade dissections and looking forward to the evaluation.”

Using IVUS, the new study will evaluate the dissection rates of 15 patients following treatment of femoropopliteal denovo or no-stent restenosis by the Flex Dynamic Scoring Catheter and plain old balloon angioplasty (POBA).

VentureMed Group was an exhibitor at Vascular Interventional Advances (VIVA) in Las Vegas and the VEITH Symposium in New York during the month of November.

For more information: www.venturemedgroup.com


Related Content

News | Peripheral Artery Disease (PAD)

March 20, 2024 — Biotronik has been granted Breakthrough Device Designation (BDD) from the US Food and Drug ...

Home March 20, 2024
Home
News | Peripheral Artery Disease (PAD)

February 12, 2024 — Sensome, a company pioneering the connected medical device revolution with the world’s smallest ...

Home February 12, 2024
Home
News | Peripheral Artery Disease (PAD)

November 10, 2023 —Getinge announced commercial availability of the iCast covered stent system in the United States for ...

Home November 10, 2023
Home
News | Peripheral Artery Disease (PAD)

October 24, 2023 — Four years ago, following a publication based on the limited data available, the U.S. Food and Drug ...

Home October 24, 2023
Home
News | Peripheral Artery Disease (PAD)

September 14, 2023 — LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of ...

Home September 14, 2023
Home
News | Peripheral Artery Disease (PAD)

July 11, 2023 — The U.S. Food and Drug Administration (FDA) is informing healthcare providers about updated information ...

Home July 11, 2023
Home
News | Peripheral Artery Disease (PAD)

June 21, 2023 — A new science report issued by the American Heart Association (AHA) emphasizes the importance of ...

Home June 21, 2023
Home
News | Peripheral Artery Disease (PAD)

June 16, 2023 — Endologix LLC, a privately held, global medical device company, dedicated to providing disruptive ...

Home June 16, 2023
Home
News | Peripheral Artery Disease (PAD)

June 15, 2023 — Endologix LLC, a privately held, global medical device company dedicated to providing disruptive ...

Home June 15, 2023
Home
News | Peripheral Artery Disease (PAD)

March 8, 2023 — Treatments for peripheral artery disease (PAD) were largely developed in men and are less effective in ...

Home March 08, 2023
Home
Subscribe Now